Animal Health Partners
Join Our Innovation Network
Building a collaborative ecosystem to accelerate groundbreaking therapeutics.
As a key strategic investor, Merck shares our vision of transforming veterinary medicine through the power of genetic engineering. Together, we are focused on a paradigm shift: moving away from chronic symptom management toward "one-and-done" gene therapy solutions that provide lifelong, systemic cures for severe animal diseases.
Partnering to bring our lead animal health program to market across the United States. Through this strategic alliance, we are leveraging Phibro's established commercial infrastructure and deep veterinary expertise to ensure our flagship gene therapy reaches the clinics and animals that need it most.
Partnering with a global leader in animal health to develop and commercialize our novel gene therapy for canine osteoarthritis (OA). This strategic alliance validates our approach to treating highly prevalent chronic diseases, combining our breakthrough science with their extensive reach to deliver a one-dose, disease-modifying treatment to the millions of dogs suffering from joint pain.
Dedicated to closing the gap between human and veterinary medicine, Protect Animal Health shares our commitment to elevating pet healthcare to human-grade standards. By combining our advanced gene therapy platform with Protect’s deep expertise in companion animal drug incubation, we are collaborating to tackle highly prominent, age-related diseases in pets. Together, we are working to bring transformative, life-extending therapeutics to market for the animals we consider family.